Artiva Biotherapeutics, Inc.

Filed a patent for "chimeric antigen receptors and use thereof" on Wed, June 14, 2023

Filed a patent for "expanded and stimulated natural killer cells" on Thu, February 22, 2024

Filed a patent for "chimeric antigen receptor comprising an anti-her2 antibody or antigen-binding fragment thereof and natural killer cells comprising the same" on Wed, October 4, 2023

Filed a patent for "treatment of cancer with nk cells and a cd20 targeted antibody" on Thu, January 4, 2024

Filed a patent for "treatment of cancer with nk cells and an egfr targeted antibody" on Wed, October 4, 2023

Filed a patent for "treatment of cancer with nk cells and a her2 targeted antibody" on Thu, June 20, 2024

Filed a patent for "treatment of cancer with nk cells and a cd38-targeted antibody" on Thu, April 11, 2024

Filed a patent for "treatment of cancer with nk cells and a cd20 targeted antibody" on Thu, June 6, 2024

Filed a patent for "chimeric antigen receptor comprising an anti-cd19 antibody or antigen-binding fragment thereof and natural killer cells comprising the same" on Wed, October 4, 2023